


Cinitapride

Chemical Properties

CAS No. :	66564-14-5
Formula:	C ₂₁ H ₃₀ N ₄ O ₄
Molecular Weight:	402.49
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Cinitapride (Blaston) is a gastroprokinetic agent. It slows the actions of the muscles to reduce the symptoms of conditions such as acid reflux, delayed gastric emptying, and ulcer dyspepsia. Cinitapride acts as an antagonist of the 5-HT ₂ receptors and as an agonist of the 5-HT ₁ and 5-HT ₄ receptors.
Targets(IC50)	5-HT Receptor, Dopamine Receptor

Solubility Information

Solubility	DMSO: 12.5 mg/mL (31.06 mM), Sonication is recommended. H ₂ O: Insoluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 1.25 mg/mL (3.11 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4845 mL	12.4227 mL	24.8453 mL
5 mM	0.4969 mL	2.4845 mL	4.9691 mL
10 mM	0.2485 mL	1.2423 mL	2.4845 mL
50 mM	0.0497 mL	0.2485 mL	0.4969 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Marquez H, Albertí J, Salvà M, Saurina J, Sentellas S. Characterization of in vitro metabolic profiles of cinitapride obtained with liver microsomes of humans and various mammal species using UHPLC and chemometric methods for data analysis. *Anal Bioanal Chem.* 2012 May;403(4):909-16.

Castro FJ, Saavedra J, López F, Herrera S, Bragulat E. [Acute cinitapride poisoning]. *Gastroenterol Hepatol.* 2011 Nov;34(9):662-3.

Marquez H, Albertí J, Salvà M, Saurina J, Sentellas S. Characterization of in vitro metabolic profiles of cinitapride obtained with liver microsomes of humans and various mammal species using UHPLC and chemometric methods for data analysis. *Anal Bioanal Chem.* 2012 May;403(4):909-16. doi: 10.1007/s00216-012-5795-z. Epub 2012 Feb 24. PubMed PMID: 22362276.

Baqai MT, Malik MN, Ziauddin F. Efficacy and safety of cinitapride in functional dyspepsia. *J Pak Med Assoc.* 2013 Jun;63(6):747-51.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481